BioNTech holds a total of 239.77 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.11 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as BioNTech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioNTech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividends Paid is expected to grow at the current pace this year. Common Stock Shares Outstanding is expected to rise to about 260.6 M this year. Net Income Applicable To Common Shares is expected to rise to about 12.4 B this year.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioNTech
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
BioNTech Stock Ownership Analysis
About 65.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.4. In the past many companies with similar price-to-book ratios have beat the market. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.05. The entity recorded earning per share (EPS) of 18.0. The firm last dividend was issued on the 6th of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people. For more info on BioNTech SE please contact the company at 49 6131 9084 0 or go to https://www.biontech.de.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.